<code id='E32D903979'></code><style id='E32D903979'></style>
    • <acronym id='E32D903979'></acronym>
      <center id='E32D903979'><center id='E32D903979'><tfoot id='E32D903979'></tfoot></center><abbr id='E32D903979'><dir id='E32D903979'><tfoot id='E32D903979'></tfoot><noframes id='E32D903979'>

    • <optgroup id='E32D903979'><strike id='E32D903979'><sup id='E32D903979'></sup></strike><code id='E32D903979'></code></optgroup>
        1. <b id='E32D903979'><label id='E32D903979'><select id='E32D903979'><dt id='E32D903979'><span id='E32D903979'></span></dt></select></label></b><u id='E32D903979'></u>
          <i id='E32D903979'><strike id='E32D903979'><tt id='E32D903979'><pre id='E32D903979'></pre></tt></strike></i>

          Home / explore / explore

          explore


          explore

          author:hotspot    Page View:1794
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In